Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared an article on X authored by Stavroula L. Kastora et al.:
“Safety of topical estrogen therapy during adjuvant endocrine treatment among patients with breast cancer: A meta-analysis based expert panel discussion
Topical oestrogen use does not appear to increase recurrence or mortality risk in breast cancer survivors on tamoxifen.
Topical oestrogen use during aromatase inhibitors may raise recurrence risk, though mortality risk appears unaffected.
An adequately powered prospective study with extended follow-up is recommended to resolve clinical uncertainty on recurrence.”
Authors: Stavroula L. Kastora et al.
